A Twelve-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5 Mg QD, 1 Mg QD and 1 Mg BID of Alosetron in Female Subjects With Severe Diarrhea-Predominant IBS Who Have Failed Conventional Therapy.

Trial Profile

A Twelve-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5 Mg QD, 1 Mg QD and 1 Mg BID of Alosetron in Female Subjects With Severe Diarrhea-Predominant IBS Who Have Failed Conventional Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Alosetron (Primary)
  • Indications Irritable bowel syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jul 2012 Quality-of-life effects and treatment satisfaction results published in Alimentary Pharmacology and Therapeutics.
    • 23 Dec 2010 Additional location (Australia) added as reported by NCT00067561.
    • 03 May 2010 QOL and patient satisfaction results were reported at DDW 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top